NCT03114631View on ClinicalTrials.gov

Dendritic Cell Immunotherapy for the Patients With Pancreatic Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

January 9, 2017

Primary Completion Date

May 3, 2019

Study Completion Date

May 23, 2019

Conditions
Dendritic CellsPancreatic Neoplasms
Interventions
BIOLOGICAL

Dendritic cells pulsed with tumor lysate

BIOLOGICAL

Dendritic cells pulsed with MUC-1/WT-1 peptides

Trial Locations (1)

220000

Minsk City Clinical Oncologic Dispensary, Minsk

All Listed Sponsors
collaborator

Belarusian State Medical University

OTHER

lead

The Republican Research and Practical Center for Epidemiology and Microbiology

OTHER

NCT03114631 - Dendritic Cell Immunotherapy for the Patients With Pancreatic Cancer | Biotech Hunter | Biotech Hunter